Deceptive advertising practices have often left a bitter taste for both consumers and regulatory bodies alike. In a world where labels often overpromise and underdeliver, a recent case from the U.S. District Court for the Central District of California serves as a poignant reminder to brand owners and marketing executives of the need to tread carefully and embrace transparency with consumers to stay in compliance with the law.

The case, Whitaker v. Pharmavite LLC (May 9, 2023), teaches about potential issues and opportunities around consumer perception, clear communication, and simple and accurate product labeling to safeguard organizations from liability.

Below, we delve into how the labeling practices of a vitamin-maker, ignited a legal battle under New York and California law, and what steps brands can take to avoid costly litigation and prevent the erosion of consumer trust.

Whitaker v. Pharmavite LLC

In Whitaker v. Pharmavite LLC, the plaintiffs initiated a lawsuit alleging that the defendant violated various consumer protection laws because the labeling of its “Extra Strength” chewable vitamin C tablets implied a higher potency of vitamin C than what was actually contained in the product.

The tablets’ front label proudly proclaimed, “Extra Strength” with a dosage of “1,000 mg per serving.” Alongside this product, however, Pharmavite also offered what the court described as “Regular Strength” chewable vitamin C tablets, which featured a dosage of 500 mg per serving. Based on the “Extra Strength” labeling, the plaintiffs believed that each tablet contained a higher amount of vitamin C compared to a “Regular Strength” tablet. The reality was, however, that both the “Extra Strength” and “Regular Strength” products contained the same 500 mg per tablet of vitamin C. The only difference was that the “Extra Strength” product included an instruction on the back label advising consumers to take two tablets per day instead of one.

Pharmavite filed a motion to dismiss primarily based on the argument that the plaintiffs' claims failed to meet the “reasonable consumer” standard, which serves as the benchmark for evaluating deceptive packaging claims. In other words, it argued that the plaintiffs' claims failed as a matter of law because no reasonable consumer would be deceived by the “Extra Strength” label and expect one tablet to contain 1,000 mg of vitamin C.

The Court’s Opinion

The court found little merit in Pharmavite's argument, and the opinion provides useful insights into the court’s evaluation under the “reasonable consumer” standard.

First, context matters. The court emphasized the importance of considering how real consumers perceive and react to advertising. Reasonable consumers don't typically peel through every detail on a product's label before making a purchase. Therefore, even if accurate information is provided on a back label, a misleading representation on the front label can still deceive consumers.

Clear and unambiguous labeling is key. In this instance, the term “Extra Strength” was likely to lead consumers to believe that the product contained a higher dosage of vitamin C, yet both the “Extra Strength” and the “Regular Strength” products contained the same amount. Brands need to ensure that labeling and marketing claims accurately reflect a product's attributes to avoid misleading consumers.

The court noted that consumers may have certain expectations based on a product's labeling. In this case, the use of the term “Extra Strength” without adequate clarification to its meaning led consumers to assume a higher potency. Brand owners need to consider how consumers interpret labeling elements and strive to meet those expectations to avoid deceptive practices.

The court added that consumers should not have to cross-check multiple products' ingredient lists or perform calculations to ensure they are purchasing the intended product. It is the obligation of a brand to ensure that the product's qualities and claims are accurately represented on the packaging.

Brand Owner Lessons:

Whitaker v. Pharmavite LLC serves as a reminder for brand owners and creators of packaging of the importance of clear and accurate labeling. To avoid deceptive advertising claims, consider the following:

1. Labeling Accuracy: Ensure that information displayed on the packaging aligns with the product's actual attributes. Misleading claims or ambiguous terminology can cause consumer confusion and lead to legal consequences.
2. Consumer Perception: Take into account how reasonable consumers would perceive and understand the product's labeling and marketing. Anticipate their expectations and avoid creating misleading impressions through labeling design and terminology.
3. Clear Communication: Be transparent and provide clear instructions, serving sizes, and dosage information. Ambiguity on front labels can be misleading to consumers, even if more detailed information is available elsewhere on the packaging.
4. Avoid Unnecessary Complexity: Consumers should not be burdened with complex comparisons or calculations to make informed purchasing decisions. To avoid confusion keep the information simple, easily accessible, and straightforward.

Conclusion

Ambiguous claims or misleading terminology can lead to consumer confusion with legal repercussions. Whitaker v. Pharmavite LLC is a reminder that brands would do well to embrace transparency to maintain compliance with consumer protection laws. In heeding these lessons, brand owners can establish trust with customers and avoid the pitfalls of deceptive packaging.